

# Index

- AD. *See* Alzheimer's disease  
 aducanumab, 100–101  
 age, prevalence of PD, 21  
 Alessi, Dario, 7, 68  
 Aligning Science Across  
   Parkinson's (ASAP),  
   144–146  
 alpha-synuclein  
   animal models, 45  
   biomarker, 73, 74–75  
   combined with other  
   markers, 75–76  
   cause of PD, 8–9, 17–18,  
   44–45, 46–50, 52  
   may be protective, 49–50  
   SNCA mutations, 15, 44–45  
   therapeutic target, 52  
   unknowns, 123  
 alternative medicine, 5–6, 30  
 Alzheimer's disease (AD)  
   A/T/N diagnostic model,  
   113–117  
   brain protein pathology  
   causative or protective?,  
   41–42, 46–48, 51,  
   59–63, 65, 95–96  
   co-pathology with PD,  
   42–43, 57, 64, 103  
   discrepancy between  
   scientific and lay view of  
   the disease, 111–112  
   funding for research, 96, 97  
   prodromal phase, 62, 97–100  
   treatment, 51, 96–101,  
   112–113, 116–117  
 amyloid, 41–42  
   anti-amyloid therapies, 51,  
   96–101, 112–113,  
   116–117  
   cause or effect?, 46–48, 51,  
   59–63, 65, 95–96,  
   112–113  
   marker of AD, 111, 113–117  
   PD, 74  
   protective strategy, 65, 117  
   sleep deprivation, 123  
 amyloid precursor protein  
   (APP), 95–96  
 animal models, 14, 45, 64–65,  
   139–141  
 anosmia, 17  
 apolipoprotein E, 60  
 apoptosis, 129  
 astronomy, 118  
 AUC (area under the ROC  
   curve), 75  
*Awakenings* (film), 12  
 beta-amyloid. *See* amyloid  
 big data, 34, 76, 78–79  
 biomarkers, 71–79  
   alpha-synuclein, 73, 74–75  
   amyloid, 111, 113–117  
   combinations, 75–76  
   definition, ix  
   do not correlate with clinical  
   subtype, 25–26, 36,  
   73–75, 149  
   Lewy bodies, 2, 16, 44  
   population studies, 133–135,  
   141, 149  
   PPMI, 25, 73, 78  
   tau, 73, 75  
 Bloem, Bas, 54  
 Braak hypothesis, 16–18, 50  
 Bradford Hill criteria, 46–48  
 brain bank studies, 34–36,  
   65  
   oldest old, 59–63  
 breast cancer, 81, 82, 127  
 Brin, Sergey, 145  
 Burke, Robert, 18, 48–50  
 cancer, 81–83, 127  
 cardiovascular disease, 112  
 Carlsson, Arvid, 11  
 Carrillo, George, 13  
 causes of neurodegenerative  
   diseases  
   AD, 46–48, 51, 59–63, 95–96  
   in an individual, 21–22  
   PD  
   alpha-synuclein  
   misfolding, 8–9, 15,  
   17–18, 44–45, 46–50,  
   52  
   dopamine deficiency,  
   11, 17  
   genetic, 15, 18–19  
   MPTP, 13–14  
 cell biology, complexity of,  
   128–131  
 Chan Zuckerberg Initiative  
   (CZI), 146  
 Charcot, Jean-Martin, 2  
 Chinese medicine, 5–6  
 chronic traumatic  
   encephalopathy, 65  
 Church, George, 7  
 Cincinnati Cohort Biomarker  
   Program, 135  
 clinical trials  
   AD research, 116–117  
   future directions, 139–141,  
   143, 149  
   negative results, 51, 87–89,  
   100, 106–107, 112–113  
   recruitment, 69, 100  
 clinico-pathologic model of  
   disease, 27, 57–58  
   to be replaced by systems  
   biology approach,  
   139–142  
 coenzyme Q, 89  
 cognitive resilience, 62–63,  
   64, 65  
 colon, 17  
 Contursi family, 15  
 Cotzias, George, 11–12  
 crenezumab, 97  
 Cure Parkinson's Trust  
   (CPT), 143  
 cystic fibrosis, 127  
 De Novo Parkinson (DeNoPa)  
   program, 73  
 deep brain stimulation, 92  
 definition of PD, need for  
   revision, 25–29  
 dementia  
   dementia with Lewy bodies,  
   42–43  
   Parkinson's disease  
   dementia, 42–43, 44

- with/without AD pathology, 59–63, 113–117
- diagnosis
- autopsy as the gold standard, 41–42, 63
  - by clinical criteria, 25–29
- dopamine, 11–12, 17, 87
- levodopa, 11–12, 33, 92
- dopamine-producing cells, 48–50, 129
- Drawing Hands* (Escher), 55
- dual reality, 1, 5–7
- Duck of Vaucanson, 26
- Duvoisin, Roger, 15
- epidemiology of PD, 21
- European Parkinson's Therapy Centre, 137
- exercise, 136–137
- familial PD, 15
- Framingham study, 112
- funding of research, 7, 96, 97, 144
- Gan-Or, Ziv, 108
- Gatto, Emilia, 25
- GBA* (glucocerebrosidase), 64–65, 108, 144
- genetics
- AD, 60, 95–96
  - cystic fibrosis, 127
  - genes as therapeutic targets, 108–109
- PD
- GBA*, 64–65, 108, 144
  - GWAS studies, 18–19, 108
  - LRRK*, 2, 68
  - PRKN*, 49
  - SNCA*, 15, 44–45
- geocentrism, 118
- glucocerebrosidase (*GBA*), 64–65, 108, 144
- Golbe, Lawrence, 15
- Greenamyre, Timothy, 106
- Harari, Yuval Noah, 1, 6–7
- Hartings, Jed, 126
- head trauma, 65, 126
- Hornykiewicz, Oleh, 11
- Human Cell Atlas, 146
- hypertension, 112
- IGPP Consortium, 108
- intellectual property, 85
- Jack, Clifford, 113
- journals (scientific), 53–54, 84
- Kandel, Eric, 84
- Knopman, David, 97
- Kolata, Gina, 57
- Kordower, Jeffrey H., 8
- Krauthammer, Charles, 31
- Lang, Anthony E., 69, 126
- Langston, J. William, 13
- Lashual, Hilal, 53
- LCT (Linked Clinical Trials) Program, 143
- Lee, Virginia, 123
- Lees, Andrew, 38–39
- levodopa, 11–12, 33, 92
- Lewy bodies/Lewy pathology, 2, 16, 44, 65
- Linked Clinical Trials (LCT) Program, 143
- LRRK2* (leucine-rich repeat kinase 2), 68
- Luk, Kelvin, 8
- lumbar puncture, uncomfortable, 78
- McBride, Heidi, 129–130
- Merchant, Kalpana, 144
- Michael J Fox Foundation (MJFF), 71, 77
- PPMI study, 25, 73, 78
- Mitchell, Kevin, 125–126
- mitochondria, 89, 128–130
- models of disease, 57–69, *See also* animal models
- clinico-pathologic (single disease) model, 27, 57–58
  - in oncology, 81–83, 127
  - proteinopathy, 2–3, 17–18, 41–52, 57–58
  - absence of contrary evidence, 123
  - systems biology (multi-disease) model, 28, 139–142
  - implications for treatment, 87, 106
  - overlap with single disease model, 105–107
- MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine), 13–14
- Muhammed Ali, xi
- Myerson's sign, 13
- neurofibrillary tangles (tau aggregation), 41–42, 46–48, 95
- norepinephrine, 87
- Nussbaum, Robert, 15
- odds ratio (OR), 61–62
- oldest old studies, 59–63
- oncology, 81–83, 127
- open science, 84–85
- Osler, Sir William, 27
- Palfreman, Jon, 67
- paraquat, 14
- Parkinson, James, 1–2
- Parkinson's disease (PD)
- alpha-synuclein aggregation/misfolding, 8–9, 15, 17–18, 44–45, 46–50, 52
  - may be protective, 49–50
  - animal models, 14, 45, 64–65
  - biomarkers, 73, 74–76
  - case study, 43–44
  - co-pathology with AD, 42–43, 57, 64, 103
  - diagnosis, 41–42
  - genetics
    - GBA*, 64–65, 108
    - GWAS studies, 18–19, 108
    - LRRK*, 2, 68
    - PRKN*, 49
    - SNCA*, 15, 44–45  - in history, 1–3, 146
  - Lewy bodies, 2, 16, 44, 65
  - MPTP-induced, 13–14
  - one disease or many?, 25–29, 105–107, 139–142
  - prevalence, 21
  - prodromal phase, 17
  - progression, 33, 34–36, 38, 43–44
  - monitoring, 77
  - need for markers, 108–109
  - puzzle concept, 18
  - subtypes, 25–26, 33–34
  - treatment. *See* treatment, for PD
- Parkinson's disease dementia, 42–43, 44
- Parkinson's Progression Markers Initiative (PPMI), 25, 73, 78
- patents, 85

- patient-centered research, 85  
 PD. *See* Parkinson's disease  
 personalized medicine, 68, 83,  
     103, 141, 148–149  
 pharmaceutical industry,  
     90–93, 100–101, 144  
 phenotype of PD. *See*  
     symptoms  
 physical exercise, 136–137  
 population studies  
     and biomarker  
         identification, 133–135,  
         141, 149  
     Framingham study, 112  
     PPMI, 25, 73, 78  
 postural instability-gait  
     disorder (PIGD),  
     25–26, 34  
 PPMI (Parkinson's Progression  
     Markers Initiative), 25,  
     73, 78  
 precision medicine, 68, 83, 103,  
     141, 148–149  
 Prevail Therapeutics, 144  
 prevalence of PD, 21  
 prion disease, 17–18. *See also*  
     proteinopathy model  
 PRKN (parkin), 49  
 prodromal phase  
     AD, 62, 97–100  
     PD, 17  
 progression of PD, 33, 34–36,  
     38, 43–44  
     monitoring, 77  
     need for markers, 108–109  
 proteinopathy model, 2–3,  
     17–18, 41–52, 57–58  
     absence of contrary  
         evidence, 123  
 psychiatry, 125–126  
 publication of research,  
     53–54, 84  
  
 Quackenbush, John, 109  
 quality of life, 91–92  
  
 Raphael, Karen, 136–137  
 reductionism, 26–28, 84,  
     125–127  
  
 to be replaced by systems  
     biology approach,  
         139–142  
 Reed, Alex, 137  
 research  
     funding, 7, 96, 97, 144  
     overspecialization, 58–59, 84  
     problems with, 53–54,  
         84, 103  
     splitters vs lumpers, 67  
     suggestions for change,  
         84–85  
 Riggare, Sarah, 77  
  
 Schekman, Randy, 53–54,  
     145–146  
 Scherzer, Clemens, 108–109  
 Schwartz, Thomas, 129  
 sensitivity, 63  
 Sherer, Todd, 38, 77  
 Silverstein Foundation, 144  
 sleep deprivation, 123  
 smell, loss of sense of, 17  
 SNCA, 15, 44–45. *See also*  
     alpha-synuclein  
 solanezumab, 97  
 specificity, 63  
 spermidine, 45  
 spinal taps, uncomfortable, 78  
 Stamford, Jon, 85  
 Stefanis, Leonidas, 49  
 stem cells, 30–31, 128  
 Stott, Simon, 8–9  
 stroke, 126  
 substantia nigra, 13, 65  
 subtypes, 33–39  
     and biomarkers, 25–26, 36,  
         73–75, 149  
     population studies can  
         identify, 112  
     treatment must be subtype-  
         specific, 68–69, 139, 148  
 Sulzer, David, 129  
 symptoms, 25–26, 30, 33,  
     43–44  
     as observed by  
         Parkinson, 1–2  
 systems biology (multi-disease)  
     model, 28, 139–142  
  
 implications for treatment,  
     87, 106  
 overlap with single disease  
     model, 105–107  
  
 Tanenbaum Open Science  
     Institute, 85  
 tau, 41–42, 46–48, 95  
     as a biomarker, 73, 75  
     combined with other  
         markers, 75–76  
     chronic traumatic  
         encephalopathy, 65  
 toxins (MPTP), 13–14  
 traditional Chinese  
     medicine, 5–6  
 trajectory of PD, 33, 43–44  
 traumatic brain injury, 65, 126  
 treatment  
     for AD, 51, 96–101, 116–117  
     for PD  
         alpha-synuclein  
             targeted, 52  
         deep brain stimulation,  
             92  
         dopamine replacement,  
             11–12, 33, 87, 92  
         exercise, 136–137  
         experts' best bets, 8  
         failures, 81, 87–89, 148  
         fake, 5–6, 30–31  
         implications of multi-  
             disease model, 87, 106  
         research initiatives, 143  
         subtype-specific, 68–69,  
             139, 148  
         role of the pharmaceutical  
             industry, 90–93,  
             100–101, 144  
 tremor dominant (TD) disease,  
     25–26, 34  
  
 Unified Parkinson's Disease  
     Rating Scale  
     (UPDRS), 77  
  
 verubecestat, 97  
  
 Zuckerberg, Mark, 146